Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects.
Krause
Fabian
F
Younger
Alastair
A
Weber
Martin
M
D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000009:adverse effects; D001859:Bone Neoplasms / Q000139:chemically induced / Q000517:prevention & control*; D016025:Bone Transplantation; D000075202:Contraindications; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D011358:Product Surveillance, Postmarketing; D011994:Recombinant Proteins / Q000009:adverse effects; D013978:Tibial Fractures / Q000628:therapy*; D016212:Transforming Growth Factor beta / Q000009:adverse effects
D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2